Image For Activity Cover
October 18, 2021- ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series- OnDemand
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
First time Users
First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, login before proceeding.
Course Information

October 18, 2022 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Not all BRCA Mutations Respond to Platinums the same”

 

Date of Release: November 4, 2021

Expiration Date: October 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

www.acmgeducation.net


Course Description

Dr. Michael Pishvaian from Johns Hopkins University presents “Not all BRCA mutations respond to platinums the same”.  Variants in the BRCA1 and BRCA2 genes have been widely associated with sensitivity to platinum therapies in many cancer types, including pancreatic cancer as seen in this case presentation.  As genomic testing has become more accessible and corresponding clinical research has evolved, we have learned more about how variants within BRCA1 and BRCA2 correspond to sensitivity to platinum therapy.  Not all BRCA variants confer the same therapeutic response.  Register to participate in this exciting session to learn more.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Learning Objectives

At the conclusion of this session, participants should be able to:

  1. Describe the genomic testing methods used to detect genomic variants in this case.
  2. List the resources used to interpret the variant(s) observed.
  3. Explain the features of the BRCA1/2 variants that confer sensitivity to platinum therapy.

 

Moderator: